Tempest Therapeutics (TPST)
Develops in vivo CAR-T candidates for autoimmune disease and cancer.
Something off on this page? Send us feedback.
Develops in vivo and autologous CAR-T candidates alongside oncology small molecules, with near-term emphasis on a CD7-targeted mRNA/lipid-nanoparticle platform. Programs generate no product revenue and advance through partners, external trials, and third-party manufacturing.
Advances a cell-therapy and small-molecule portfolio for autoimmune disease, cancer, and selected oncology indications. Its in vivo CAR-T platform is led by TPST-4003, which uses CD7-targeted mRNA/lipid-nanoparticle delivery and a dual CD19/BCMA CAR design; separate programs address non-B-cell blood cancers and solid tumors.
Also holds a clinical-stage autologous CAR-T candidate for multiple myeloma and POEMS syndrome, amezalpat for hepatocellular carcinoma, and TPST-1495 for familial adenomatous polyposis. Amezalpat's next-stage study requires a partnership or separate funding, while TPST-1495 is planned through an NCI-supported trial network.
Runs one discovery-and-development segment with no approved products or product-sale revenue. Its small workforce and lack of owned manufacturing make execution dependent on partners, contractors, externally supported trials, regulatory acceptance, and financing.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $779.0K · Total debt $7.6M · Total assets $9.6M · Shareholders' equity −$1.1M
- Revenue
- $0
- Operating income
- −$5.3M
- Net income
- −$5.2M
No dividends on record.
| Institutions20 holders · as of Mar 31, 2026 | 3.49% | 517.1K shares | |
| Insiders4 holders · as of Jun 8, 2026 | 37.40% | 5.54M shares | |
| Otherremainder | 59.11% | 8.75M shares |
14.81M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Matthew Angel1Insiderdirector, 10 percent owner, officer: CEO and President | 37.36% | 5.53M | 13Dfiled Mar 25, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 1.58% | 233,888 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.59% | 86,990 | 13Fas of Mar 31, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.47% | 68,908 | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 0.26% | 39,068 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
- Matthew Angel's transaction reports restate only vehicles that traded; the 2026 ownership statement (5.53M) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 24, 2026 | Matthew Angel | director, 10 percent owner, officer: CEO and President | +694,446 | $2.16 |
- AstraZeneca (ADR)
Direct dual CD19/BCMA CAR-T and in vivo CAR-T overlap.
- Johnson & Johnson
Approved BCMA CAR-T sets the multiple-myeloma benchmark.
- Bristol-Myers Squibb
Approved BCMA CAR-T competes for relapsed myeloma care.
- Gilead Sciences
Anito-cel and Kite expand BCMA and CD19 CAR-T pressure.
- Exelixis
Cabometyx is an established HCC and RCC treatment rival.
- Allogene Therapeutics
Allogeneic CD19 CAR-T targets autoimmune immune reset.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Tempest Therapeutics | $1.10 | 0.00% | $17.6M | — | — | — | — |
| AstraZeneca (ADR) | $163.26 | +0.99% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Johnson & Johnson | $274.78 | −0.17% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Bristol-Myers Squibb | $67.65 | −0.01% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Gilead Sciences | $149.20 | −0.27% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| Exelixis | $59.11 | +0.96% | $14.71B | 18.3 | 15.8 | 6.0 | +10.6% |
| Allogene Therapeutics | $1.98 | 0.00% | $683.4M | — | — | 147.3 | — |
| Median | 21.3 | 15.8 | 6.1 | +6.6% |